Abhay Dhand1, George Sakoulas2. 1. Westchester Medical Center, New York Medical College, Valhalla, New York. 2. University of California, San Diego School of Medicine, La Jolla, California. Electronic address: gsakoulas@ucsd.edu.
Abstract
PURPOSE: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as one of the most important nosocomial pathogens. Resistance to antibiotic therapy has been known to emerge especially in clinically complex scenarios, resulting in challenges in determining optimal treatment of serious MRSA. Daptomycin, in combination with other antibiotics, has been successfully used in the treatment of these infections, with the aims of resulting in reducing the prevention of antimicrobial resistance and increased killing compared with daptomycin monotherapy. METHODS: This article reviews all the published studies that used daptomycin combination therapy for the treatment of bacteremia and associated complicated infections caused by gram-positive organisms, including MRSA. We discuss the rationale of combination antibiotics and the mechanisms that enhance the activity of daptomycin, with special focus on the role of β-lactam antibiotics. FINDINGS: There are limited clinical data on the use of daptomycin in combination with other antibiotics. Most of this use was as successful salvage therapy in the setting of failing primary, secondary, or tertiary therapy and/or relapsing infection. Synergy between β-lactams and daptomycin is associated with several characteristics, including increased daptomycin binding and β-lactam-mediated potentiation of innate immunity, but the precise molecular mechanism is unknown. IMPLICATIONS: Use of daptomycin in combination with other antibiotics, especially β-lactams, offers a promising treatment option for complicated MRSA bacteremia in which emergence of resistance during treatment may be anticipated. Because it is currently not possible to differentiate complicated from uncomplicated bacteremia at the time of presentation, combination therapy may be considered as first-line therapy, with de-escalation to monotherapy in uncomplicated cases and cases with stable pharmacologic and surgical source control.
PURPOSE: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as one of the most important nosocomial pathogens. Resistance to antibiotic therapy has been known to emerge especially in clinically complex scenarios, resulting in challenges in determining optimal treatment of serious MRSA. Daptomycin, in combination with other antibiotics, has been successfully used in the treatment of these infections, with the aims of resulting in reducing the prevention of antimicrobial resistance and increased killing compared with daptomycin monotherapy. METHODS: This article reviews all the published studies that used daptomycin combination therapy for the treatment of bacteremia and associated complicated infections caused by gram-positive organisms, including MRSA. We discuss the rationale of combination antibiotics and the mechanisms that enhance the activity of daptomycin, with special focus on the role of β-lactam antibiotics. FINDINGS: There are limited clinical data on the use of daptomycin in combination with other antibiotics. Most of this use was as successful salvage therapy in the setting of failing primary, secondary, or tertiary therapy and/or relapsing infection. Synergy between β-lactams and daptomycin is associated with several characteristics, including increased daptomycin binding and β-lactam-mediated potentiation of innate immunity, but the precise molecular mechanism is unknown. IMPLICATIONS: Use of daptomycin in combination with other antibiotics, especially β-lactams, offers a promising treatment option for complicated MRSA bacteremia in which emergence of resistance during treatment may be anticipated. Because it is currently not possible to differentiate complicated from uncomplicated bacteremia at the time of presentation, combination therapy may be considered as first-line therapy, with de-escalation to monotherapy in uncomplicated cases and cases with stable pharmacologic and surgical source control.
Authors: Kimberly C Claeys; Evan J Zasowski; Anthony M Casapao; Abdalhamid M Lagnf; Jerod L Nagel; Cynthia T Nguyen; Jessica A Hallesy; Mathew T Compton; Keith S Kaye; Donald P Levine; Susan L Davis; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Matthew P Cheng; Alexander Lawandi; Guillaume Butler-Laporte; Katryn Paquette; Todd C Lee Journal: Trials Date: 2018-05-29 Impact factor: 2.279
Authors: Erin K McCreary; Ravina Kullar; Matthew Geriak; Evan J Zasowski; Khulood Rizvi; Lucas T Schulz; Krista Ouellette; Logan Vasina; Fadi Haddad; Michael J Rybak; Marcus J Zervos; George Sakoulas; Warren E Rose Journal: Open Forum Infect Dis Date: 2019-12-31 Impact factor: 3.835
Authors: Alfredo Aires; Eduardo Marrinhas; Rosa Carvalho; Carla Dias; Maria José Saavedra Journal: Biomed Res Int Date: 2016-04-14 Impact factor: 3.411
Authors: D Rodriguez-Pardo; C Pigrau; D Campany; V Diaz-Brito; L Morata; I C de Diego; L Sorlí; S Iftimie; R Pérez-Vidal; G García-Pardo; T Larrainzar-Coghen; B Almirante Journal: Eur J Clin Microbiol Infect Dis Date: 2016-05-14 Impact factor: 3.267
Authors: Courtney N Nichols; Lynn C Wardlow; Kelci E Coe; Mohammad Mahdee E Sobhanie Journal: Open Forum Infect Dis Date: 2021-06-22 Impact factor: 3.835